CYKOR LLC: $11.2M Department of Veterans Affairs Contract

The Department of Veterans Affairs awarded Cykor LLC, a subsidiary of Leidos Holdings (LDOS), an $11.2M delivery order to support the provider directory for the Veteran Community Care Program. This program allows veterans to receive care from community providers outside the VA system, and the directory is a critical IT infrastructure component. The contract runs from April 2026 to April 2027. Leidos is the publicly traded parent company (ticker: LDOS) with annual revenue of approximately $16.5B. The $11.2M award represents roughly 0.04% of Leidos' total revenue — a small but positive increment. Leidos' Health segment, which generated ~$2.5B in FY2025, focuses on federal health IT, including the VA's electronic health record modernization and community care systems. This contract adds to the segment's backlog and demonstrates continued customer trust. None of the 20 related bill signals in the HillSignal database directly authorize or appropriate funding for this contract. The bills listed are overwhelmingly focused on finance (CFPB rules, prediction markets, terrorism risk insurance), energy (fuel taxes, EPA waivers), and other non-healthcare areas. The most relevant healthcare bill, HR8622 (Medicare Physician Data-driven Performance Payment System Act), is neutral and unrelated to VA community care. This contract likely draws from previously appropriated VA discretionary funds, not new legislation. Supply chain beneficiaries are limited. The provider directory is a software service; potential subcontractors could include small IT firms specializing in healthcare data management, but no publicly traded companies are identifiable from this award alone. Competitor CACI International (CACI) may face minor competitive displacement, as it also pursues VA health IT contracts. Historically, VA health IT contracts tend to be stable, multi-year relationships. Leidos has held similar VA contracts for years, and this delivery order is consistent with a pattern of incremental renewals and expansions. Such awards typically have no material impact on Leidos' stock price given their small size relative to the company's overall revenue.